Macroagregados De Albúmina Humana (Macrosalb (99mtc))

The compound consists of albumin particles labeled with technetium‑99m. After injection, the particles lodge in the small vessels of the lung capillary network. The technetium‑99m emits gamma photons that are captured by a gamma camera, producing a detailed image of regional lung perfusion.

The dose of Technetium‑99m macroaggregated human albumin is determined by the prescribing physician or nuclear medicine specialist. The amount is calculated based on the patient’s age, weight, and the specific imaging protocol, and is prepared from the supplied kit immediately before administration.

Safety in pregnancy and breastfeeding has not been definitively established. Use is generally avoided unless the diagnostic information is essential and cannot be obtained by alternative methods. If administered, the potential radiation exposure to the fetus or infant should be carefully considered and discussed with a specialist.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Technetium‑99m macroaggregated human albumin is the standard agent for lung perfusion imaging because of its optimal particle size, reliable capillary trapping, and well‑characterized radiation profile. Alternative agents, such as newer radiolabeled compounds, may offer different imaging characteristics but are less widely validated and may not be available in all regions.

The kit should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the vial. Before use, reconstitute according to the manufacturer’s instructions in a clean, aseptic environment to maintain sterility and radiochemical integrity.

The reconstituted solution is administered intravenously, typically as a rapid bolus injection. Administration is performed by qualified healthcare personnel in a nuclear medicine suite, with appropriate radiation safety measures in place to protect both the patient and staff.

Serious risks include severe allergic reactions such as anaphylaxis, unexpected pulmonary hypertension, and rare embolic events caused by particle aggregation. Radiation exposure is also a consideration; therefore, the lowest effective activity should be used and all radiation protection guidelines must be followed.

Patients with known hypersensitivity to albumin, technetium‑99m, or any component of the kit should not receive the product. It is also contraindicated in pregnant women unless absolutely necessary, and in individuals where the diagnostic benefit does not outweigh the potential radiation risk.